SEC Tracker
Get the app

Impact Biomedical IBO

Impact Biomedical reported a net loss of $645,000 for the three months ended Sep 30, 2026.

Impact Biomedical (IBO) filed a 10-Q with the SEC on Nov 9, 2026, 4:50 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $21,000 for the three months ended Sep 30, 2026.
  2. Diluted EPS was -$0.08 for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $21,000 as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued.”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 7, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Impact Biomedical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.